Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofosbuvir + velpatasvir + ribavirin
- Development stage
- Phase 4
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A powerful antiviral regimen used primarily for treating chronic hepatitis C virus (HCV) infection. This combination therapy includes sofosbuvir (a nucleotide analog inhibiting NS5B polymerase), velpatasvir (targeting the NS5A protein), and ribavirin (a broad-spectrum antiviral that enhances efficacy). The regimen is particularly effective for treating HCV genotypes 1-6, with high efficacy rates (95-99% SVR) in patients with or without cirrhosis, and is valuable for those with decompensated cirrhosis or who have failed previous direct-acting antiviral therapies.
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on sofosbuvir + velpatasvir + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofosbuvir + velpatasvir + ribavirin.